Assessment of Corneal Topography and Densitometry in Rheumatoid Patients
1 other identifier
observational
40
1 country
2
Brief Summary
Corneal transparency is a result of its unique ultrastructure with collagen fibrils regularity, integrity of connective tissue, and balanced keratocyte components. Corneal densitometry is known to be altered in cases corneal haze or scar, but recently it is assumed to be altered earlies in presence of a systemic inflammatory disease, even before clinical manifestations take place. The aim of this study is to assess changes in corneal topography and corneal densitometry in RA patients with clinically clear corneas and to compare these results with those of healthy control subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2023
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
December 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedFirst Posted
Study publicly available on registry
January 6, 2025
CompletedMay 1, 2025
April 1, 2025
1 year
December 28, 2024
April 29, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Corneal topographic changes and densitometry in patients with rheumatoid arthritis
one year
Study Arms (1)
Rheumatoid arthritis patients
Pentacam
Eligibility Criteria
All patients have RA presented for ophthalmic clinic during the period of the study
You may qualify if:
- Patients diagnosed with rheumatoid arthritis
You may not qualify if:
- corneal opacity; severe dry eye; glaucoma; any inflammatory ocular disorder or infection including blepharitis, conjunctivitis, meibomitis and dacryocystitis; central or peripheral thinning evident in slit-lamp examination; history of ocular surgery, trauma, or contact lens use; and patients using any topical medication other than artificial tears will be excluded from the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (2)
Amr Mounir
Sohag, Egypt
Elshimaa A.Mateen
Sohag, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Elshimaa A.Mateen, Doctor
Assistant Professor
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
December 28, 2024
First Posted
January 6, 2025
Study Start
January 1, 2023
Primary Completion
January 1, 2024
Study Completion
January 1, 2025
Last Updated
May 1, 2025
Record last verified: 2025-04